Rubicon Research is an R&D-driven pharmaceutical formulations company focused on the US regulated market, with about 98% of revenue in US dollars, built on specialty products, drug-device combinations and complex generics. This quarter's print will speak to whether the operating EBITDA margin holds above the newly raised 'at least 23%' FY27 guidance as ESOP, Arinna and pre-revenue costs kick in, and how gross margin absorbs the freight and input-cost escalation from the West Asia conflict.
| Results date | November 05, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 5,343 Mn (Rs. 534 Cr), up 51.6% YoY |
| Previous quarter PAT | Rs. 848 Mn, up 95.8% YoY |
| Previous quarter EBITDA margin | 24.2% (Operating EBITDA margin) |
| Market cap | Rs. 26,660.07 Cr |
| CMP | Rs. 1,610.5 |
The Board of Directors will meet on November 5, 2026 to approve the un-audited standalone and consolidated results for Q2 and H1 FY27 (quarter ended September 30, 2026). The trading window has been closed from October 1, 2026 until 48 hours after the results.
The earnings call for Q2/H1 FY27 is scheduled for November 5, 2026 at 5:30 PM IST. Speakers are CEO Parag Sancheti, CFO Nitin Jajodia and SVP Sagar Oak, moderated by Motilal Oswal.
The quarter's central test is whether Rubicon can hold its operating EBITDA margin near Q1 FY27's 24.2% while absorbing ESOP 2026 costs, Arinna upfront growth-enabler costs, and pre-revenue costs at the New Jersey and Pithampur sites, all inside the FY27 guidance of at least 23% that was revised up from 22%-23% at the Q1 call.
The cost backdrop worsened through the July-September window: Brent breached $100/bbl on September 9, Strait of Hormuz transits hit their lowest since May by September 7, and India-US container freight reportedly rose from about $1,500 to about $10,000 per 40-ft container — the same 'raw material/logistics cost escalation from global political turmoil' sensitivity the CFO confirmed on the Q4 FY26 call.
On the demand side, US generic drug pricing remained benign through the window, leaving Rubicon's price trajectory resting on its specialty mix, which reached 36% of gross profit in Q1 FY27 against an average unit price increase of +8.0% between FY22-25 versus industry erosion of -5.2%.
Tariff policy brought no direct incidence on the company's generics — imported generics stay at 0% US tariff for two years from August 1, 2026, and the Section 232 100% tariff covers specified patented pharmaceuticals only — though the overhang stays live for a company with ~98% USD revenue.
The rupee moved from about 94.65 in late June to 95.98 by September 29, roughly a 1.4% USD appreciation that is a translation tailwind to reported revenue but, per the Q1 FY26 precedent, can also bring marginal EBITDA drag via MTM losses on forex hedges.
The clearest testable promise for the quarter is the normalisation of delayed GST refunds in Q2 operating cash flow, after Q1's net operating cash flow of Rs. 285 Mn was dragged by the delay, with net working capital days already at 114 versus the ~126 guided.
Guidance scorecard to interrogate: Management's stated targets and where each stood as of the last update:
USFDA inspections and regulatory cadence: Post-quarter inspection outcomes and the approval pipeline are likely to draw scrutiny:
Cash flow, Arinna costs and governance: Balance-sheet and execution items management has put dates or numbers against:
The commercialization rate slipped to 88% in Q1 FY27 from 92%-93% in prior quarters, and an analyst on the Q1 call flagged that the rate of approvals seems to be marginally slowing down. Management factors in conservatism for regulatory variability, changes in FDA guidelines, approval delays and API supply constraints.
At the Q1 FY27 call, management revised its FY27 operating EBITDA margin guidance upwards to at least 23% from the earlier 22%-23% range, stating the guidance is at a consolidated level and takes into account growth investments in Arinna. Q1 FY27 printed a 24.2% operating EBITDA margin, above the original band.
Management has targeted R&D spend of Rs. 500 Cr (INR 5 billion) across nine quarters spanning FY26, FY27 and Q1 FY28, and says it is on track — FY26 delivered Rs. 1,935 Mn. R&D expense is guided at 10%-11% of operating revenue over the next 4-5 years, and was 10.9% in Q1 FY27.
The Pithampur facility is on track for commercial operations in Q1 CY2027, with validation expected mid-CY26. Management expects gross margin to return to the 67%-68% range once Pithampur ramps up and reliance on outsourced manufacturing reduces.
Disclaimer: This earnings preview is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.